RDOR3 after 2Q26: Hospital pricing and oncology offset lower occupancy while SulAmérica margins jump
How to read Rede D'Or's second-quarter package — R$14.9bn net revenue (+5.6% YoY), R$2.90bn EBITDA, record hospital revenue at R$9.87bn, oncology up 22.3%, SulAmérica loss ratio at 78.1%, IFRS 17 vs management net income, and net financial expense up 35.5%.
RDOR3 after 2Q26: Hospital pricing and oncology offset lower occupancy while SulAmérica margins jump
On 12 August 2026, Rede D'Or São Luiz published its 2Q26 results (reference date 30 June 2026). Consolidated net revenue reached R$ 14.91 billion, up 5.6% year on year. Consolidated EBITDA totaled R$ 2.90 billion (+18.2%), with margin widening to 19.5% from 17.4%. Reported net income under IFRS 17 hit R$ 1.29 billion (+23.1%). The headline numbers look strong across the board. The useful lesson is structural: Rede D'Or is two businesses in one ticker — hospitals and oncology on one side, SulAmérica insurance on the other — and the quarter also shows how IFRS 17 accounting can widen the gap between reported and management earnings. Reading the package means separating operating momentum from insurance accounting, and from a R$ 745 million financial expense line that grew faster than profit.
What the earnings package actually shows
Figures below follow Rede D'Or's 2Q26 earnings release (IFRS, Brazilian reais):
| Metric (2Q26) | Result | vs 2Q25 |
|---|---|---|
| Gross revenue | R$ 16.02 bn | +5.9% |
| Net revenue | R$ 14.91 bn | +5.6% |
| EBITDA | R$ 2.90 bn | +18.2% |
| EBITDA margin | 19.5% | +2.1 p.p. |
| EBITDA incl. insurer investment income | R$ 3.42 bn | +22.3% |
| Reported net income (IFRS 17) | R$ 1.29 bn | +23.1% |
| Net income ex-IFRS 17 | R$ 1.24 bn | +9.7% |
| Adjusted net income | R$ 1.28 bn | +8.5% |
| Net financial expense | R$ 745 m | +35.5% |
| Gross debt (30 Jun) | R$ 50.99 bn | +37.4% YoY |
| Net debt | R$ 22.80 bn | +31.8% YoY |
| Net debt / EBITDA | 1.71x | vs 1.65x in 2Q25 |
Management highlighted record hospital gross revenue, double-digit surgical growth, oncology expansion, and a sharp improvement in SulAmérica's loss ratio. The offset was higher interest and monetary-indexation costs as gross debt rose.
Reported profit vs management profit: the IFRS 17 gap
Rede D'Or's reported net income includes insurance accounting under IFRS 17. In 2Q26, IFRS 17 added a positive R$ 50.2 million to earnings. In 2Q25, the same standard had a negative R$ 82 million impact. That year-over-year swing alone explains part of why reported net income grew 23.1% while the management view grew only 9.7%.
| Net income measure (2Q26) | Amount | vs 2Q25 |
|---|---|---|
| Reported (IFRS 17) | R$ 1.29 bn | +23.1% |
| Ex-IFRS 17 (management) | R$ 1.24 bn | +9.7% |
| Adjusted (ex-IFRS 17 + SulAmérica acquisition amortization) | R$ 1.28 bn | +8.5% |
For a quarter-to-quarter read, the management and adjusted figures are usually the cleaner comparison. Reported profit is still the statutory number filed with the CVM, but investors comparing 2Q26 to 2Q25 should note the IFRS 17 base effect.
Hospitals and oncology: record revenue without higher occupancy
The hospital, oncology and other-services operation (before intragroup eliminations) delivered the quarter's operating story:
| Metric (2Q26) | Result | vs 2Q25 |
|---|---|---|
| Gross revenue | R$ 9.87 bn | +9.9% (record) |
| Net revenue | R$ 8.74 bn | +9.8% |
| Gross profit | R$ 2.31 bn | +20.1% |
| Gross margin | 26.5% | +2.3 p.p. |
| EBITDA | R$ 2.29 bn | +11.3% |
| EBITDA margin | 26.2% | +0.3 p.p. |
| Surgeries | 150,900 | +10.6% |
| Patient-days | 771,100 | −1.2% |
| Occupancy rate | 80.2% | −2.7 p.p. |
| Beds (end of period) | 13,600 | 76 hospitals |
Revenue growth did not come from filling more beds. Occupancy fell and patient-days declined slightly, even as the company added 110 beds during the quarter. Growth instead reflected higher revenue per patient-day (+11.2%), greater surgical volume, and a richer mix.
Surgical procedures rose 10.6% to 150,900. Elective surgeries — typically more predictable and often higher-margin — grew 11.5% and represented 72.8% of total procedures.
Oncology: fastest-growing line
Oncology was again the standout. Gross revenue reached R$ 1.15 billion, up 22.3% year on year, driven by 15.2% higher infusion volumes and 6.1% higher average revenue per infusion. Oncology's share of gross hospital revenue rose to 11.6% from 10.5% a year earlier.
Hospital service costs rose 6.5% — well below revenue growth — which pushed gross profit up 20.1% and expanded the gross margin to 26.5%. On management's adjusted basis (excluding one-offs, pro forma GSH stake), hospital EBITDA grew 18.3% with margin at 26.6%.
SulAmérica: membership growth and a lower loss ratio
SulAmérica contributed roughly half of consolidated net revenue and supplied much of the quarter's margin improvement:
| Metric (2Q26) | Result | vs 2Q25 |
|---|---|---|
| Net revenue | R$ 8.71 bn | +6.9% |
| Health + dental members | 6.1 mn | +9.7% |
| Health members | ~3.2 mn | +4.5% (+136k net adds) |
| Dental members | 2.9 mn | +16.1% |
| Consolidated loss ratio | 78.1% | vs 81.3% |
| EBITDA | R$ 612.1 m | +53.4% |
| EBITDA incl. investment income on technical reserves | R$ 1.12 bn | +53.2% |
The consolidated loss ratio improved 3.2 percentage points year on year, reflecting repricing, claims management, and fraud-prevention initiatives. Sequentially, the ratio rose 0.9 p.p. from 1Q26 — a seasonal pattern as healthcare utilization typically increases in the second quarter.
SulAmérica's standalone EBITDA more than doubled in growth terms (+53.4%), but general and administrative expenses also rose 17.7% to R$ 601.4 million, including a 38.1% increase in provisions for legal contingencies. Including investment income from assets backing insurance liabilities — standard for insurers under Brazilian reporting — adjusted EBITDA reached R$ 1.12 billion.
Financial expense and leverage: the other half of the balance sheet
Operating performance improved, but the financial line moved the other way. Net financial expense widened 35.5% to R$ 745 million. Interest and monetary-indexation expenses rose 49.1% to R$ 1.60 billion.
| Balance-sheet item (30 Jun 2026) | Amount | Trend |
|---|---|---|
| Gross debt | R$ 50.99 bn | +37.4% YoY |
| Net debt (after technical reserves) | R$ 22.80 bn | +31.8% YoY |
| Net debt / EBITDA | 1.71x | vs 1.75x in 1Q26 |
| Cash + marketable securities | R$ 47.86 bn | R$ 28.19 bn after technical reserves |
| Average debt maturity | 6 years | R$ 127 m maturing rest of 2026 |
| Average borrowing cost | CDI + 1.1 p.p. | 94.9% floating rate |
Net leverage improved slightly from 1.75x in March but remains above the 1.65x recorded a year earlier. Near-term refinancing risk looks limited — only R$ 127 million in principal matures in the remainder of 2026 — but the absolute debt stock and interest bill are growing.
Capex, cash metrics, and capital return
Rede D'Or is still expanding. Capital expenditure excluding M&A reached R$ 888.3 million in 2Q26 (+31.4%), of which R$ 772.1 million went to expansion. The company has more than 20 development projects that could add 2,690 beds through 2028.
Two cash metrics tell different stories. Management-defined cash generation in 1H26 reached R$ 5.41 billion (92.2% of reported EBITDA) — but this metric is calculated before changes in private-pension technical reserves and includes financing and investment movements. Under conventional IFRS operating cash flow, net cash from operations in 1H26 fell 47% to R$ 1.63 billion, with interest paid up 47% to R$ 2.66 billion and taxes paid up 20% to R$ 802 million.
On capital return, the company spent R$ 907 million on share buybacks in 1H26 and declared R$ 750 million in interest on equity (JCP), with R$ 400 million approved during 2Q26.
How the market read the print
Brazilian financial press coverage after the release focused on three threads: the R$ 1.2–1.3 billion profit range depending on the earnings definition, record hospital revenue with 10.6% surgical growth, and SulAmérica's margin recovery as the loss ratio fell toward 78%. Valor Econômico and Estadão highlighted the split between hospital operations (roughly half of net revenue, growing near 10%) and SulAmérica (the other half, growing 6.9%), while noting that reported profit growth was partly helped by the IFRS 17 swing. These are third-party interpretations, not audited facts, but they explain why a quarter with lower hospital occupancy can still read as operationally strong when pricing, mix, and insurance margins all move in the right direction.
How to use the explorer on this package
- Open RDOR3. Find the ITR with reference 30/06/2026 and the August 2026 earnings materials.
- Start with net revenue (R$ 14.91 bn) and split hospital (~R$ 8.74 bn) vs SulAmérica (~R$ 8.71 bn) — two engines, one consolidated margin.
- Compare reported net income (R$ 1.29 bn) with management net income (R$ 1.24 bn) before treating the +23% headline as purely operational.
- Read occupancy (80.2%, −2.7 p.p.) against revenue per patient-day (+11.2%) and oncology revenue (+22.3%) — volume and price moved in opposite directions.
- Check SulAmérica loss ratio (78.1%) and EBITDA (+53.4%) as the insurance turnaround signal.
- Cross net financial expense (R$ 745 m, +35.5%) with gross debt (R$ 50.99 bn) and net debt / EBITDA (1.71x).
- For the current quote, use the company page; this article freezes only figures already reported in the release and press.
Limits of this reading
- IFRS 17 creates non-comparable swings in reported net income; use management and adjusted figures for operational comparisons.
- Consolidated EBITDA margin (19.5%) differs from hospital segment margin (26.2%) — do not mix the two.
- Management cash generation is a non-GAAP metric and is not equivalent to IFRS operating cash flow.
- SulAmérica sequential margin changes reflect seasonal utilization patterns.
- Gross debt includes insurance technical-reserve mechanics; net debt uses cash after technical reserves.
- Press summaries may round figures or cite different earnings definitions; the CVM filing prevails.
Where to view in the explorer
Sources
- Rede D'Or São Luiz 2Q26 earnings release, 12/08/2026 — consolidated and segment figures, leverage, capex, capital return
- Valor Econômico, 12/08/2026 — hospital vs SulAmérica split, surgical volumes, occupancy, oncology
- Estadão E-Investidor, 12/08/2026 — IFRS 17 vs management net income, EBITDA, financial result
- Setor Saúde, 17/08/2026 — record hospital revenue, elective surgery mix, oncology share
- Brazil Stock Guide, 12/08/2026 — IFRS 17 impact, loss ratio, debt and interest detail
- RDOR3 on the explorer — filings and quote
Disclaimer
This article is for informational and educational purposes only. It is not investment advice. Rede D'Or reports under IFRS 17 for insurance operations; reported and management earnings can diverge materially. The company carries significant gross debt and floating-rate exposure in a high-interest-rate environment. When in doubt, the official CVM filings and Rede D'Or IR materials prevail. Refer to those documents and, if needed, a licensed professional.
Work with filings via API
Need programmatic access to DFP, ITR, FRE and more? Use the apicvm API.